April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Retinal Angiomatous Proliferation (RAP) vs. Occult Choroidal Neovascularization (O-CNV) in Exudative Age-Related Macular Degeneration Evaluated With SD Optical Coherence Tomography (SDOCT) Before and After Ranibizumab Treatment
Author Affiliations & Notes
  • M. Setaccioli
    Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • U. Introini
    Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • S. M. Giatsidis
    Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
  • A. Torres Gimeno
    Ophthalmology, Hospital Dr. Peset, Valencia, Spain
  • F. Scotti
    Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • L. Pierro
    Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • F. Bandello
    Ophthalmology, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
  • Footnotes
    Commercial Relationships  M. Setaccioli, None; U. Introini, None; S.M. Giatsidis, None; A. Torres Gimeno, None; F. Scotti, None; L. Pierro, None; F. Bandello, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 336. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Setaccioli, U. Introini, S. M. Giatsidis, A. Torres Gimeno, F. Scotti, L. Pierro, F. Bandello; Retinal Angiomatous Proliferation (RAP) vs. Occult Choroidal Neovascularization (O-CNV) in Exudative Age-Related Macular Degeneration Evaluated With SD Optical Coherence Tomography (SDOCT) Before and After Ranibizumab Treatment. Invest. Ophthalmol. Vis. Sci. 2010;51(13):336. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : to evaluate macular morphology in RAP and O-CNV using SDOCT before and after intravitreal Ranibizumab treatment.

Methods: : retrospective case series. Twenty-six eyes of 26 consecutive patients affected by AMD (7 RAP type II and 19 O-CNV) were included. Clinical evaluation and SDOCT line foveal scans and retinal maps were obtained at baseline and after the loading phase. Normal retinal morphology corresponding to the inner retinal layers, the external limiting membrane (ELM), the IS/OS junction and retinal pigment epithelium (RPE), as well as the pathologic findings corresponding to hypereflective dots, hyper- or hypo- reflective fluid and pigment epithelial detachment (PED) were graded as "present or normal": 1, or "absent or altered": 0 - Chi-square test (95% CI) and T-test (95% CI).

Results: : in O-CNV mean logMAR visual acuity was 0.38 at baseline and 0.35 after Ranibizumab loading phase, 0.39 and 0.25 in RAP group. At baseline inner retinal layers were altered in 100% RAP group and in 52.6% O-CNV (p= 0.024). RPE was normal in 71.4 % of RAP group and in 26.3% of O-CNV group (p=0.036). After the loading phase, intra- and subretinal fluid, PED and central foveal thickness were statistically decreased in the RAP group (p=0.002; 0.027 and 0.048 respectively). Compared to baseline, the O-CNV statistically lost hypereflective dots (p=0.005) and hyper reflective-fluid (p=0.003); RAP group recovered the inner retinal layers morphology (p=0.018). 31.6% of O-CNV and 57% of RAP recovered IS/OS junction integrity (p= 0.008 and p=0.018 respectively).

Conclusions: : compared to O-CNVs, RAPs show better short-term functional and morphological recovery after the Ranibizumab loading phase. This might be due to the smaller dimension, the juxtafoveal location and the intraretinal position of the RAPs. Further investigation and longer follow-up are warranted.

Keywords: age-related macular degeneration • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×